Literature DB >> 10792004

Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.

B Nikolic1, S Lee, R T Bronson, M J Grusby, M Sykes.   

Abstract

STAT4 and STAT6 are transcription factors that play crucial roles in responding to IL-12 and IL-4, respectively. STAT4 gene knockout (STAT4(-/-)) mice have markedly reduced Th1 responses and enhanced Th2 responses. STAT6(-/-) mice show the inverse phenotype. We compared the ability of bone marrow transplantation (BMT) with the inclusion of spleen cells from STAT6(-/-), STAT4(-/-), and wild-type (WT) mice to produce graft-versus-host disease (GVHD) in lethally irradiated MHC-mismatched recipients. Acute GVHD mortality was more rapid when induced by cells from STAT6(-/-) mice than when induced by STAT4(-/-) cells. However, cells from STAT4(-/-) and STAT6(-/-) donors both induced delayed GVHD mortality compared with WT controls, or compared with combined STAT4(-/-) and STAT6(-/-) cells, indicating a contribution of both Th1 cells and Th2 cells to acute GVHD. Recipients of STAT6(-/-) BMT showed evidence of acute GVHD with severe diarrhea and marked weight loss. Recipients of STAT4(-/-) BMT showed signs of GVHD with only initial transient weight loss and later development of severe skin GVHD. Histopathology showed that Th2 responses were required for the induction of both hepatic and severe skin GVHD. In contrast, both Th1 cells and Th2 cells were capable of causing intestinal pathology of GVHD. Our studies demonstrate an additive role for Th1 and Th2 cells in producing acute GVHD, and suggest a cytokine-directed approach to treating end-organ manifestations of GVHD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792004      PMCID: PMC315439          DOI: 10.1172/JCI7894

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Selective inhibition of CD4 graft-versus-host activity in IL-2-treated mice.

Authors:  M Sykes; V S Abraham; M W Harty; D A Pearson
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

2.  Increased IgE level as a marker of host-versus-graft disease: inhibition of this HVGD with a monoclonal antibody to IL-4.

Authors:  S Takai; M Tateno; T Hirano; N Kondo; S Hirose; T Yoshiki
Journal:  Cell Immunol       Date:  1993-06       Impact factor: 4.868

3.  Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease.

Authors:  K Miwa; H Hashimoto; T Yatomi; N Nakamura; S Nagata; T Suda
Journal:  Int Immunol       Date:  1999-06       Impact factor: 4.823

4.  Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection.

Authors:  H Ohdan; Y G Yang; A Shimizu; K G Swenson; M Sykes
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

5.  Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.

Authors:  N Tsukada; T Kobata; Y Aizawa; H Yagita; K Okumura
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

6.  IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.

Authors:  M Sykes; V S Abraham; M W Harty; D A Pearson
Journal:  J Immunol       Date:  1993-01-01       Impact factor: 5.422

7.  Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Authors:  W J Murphy; L A Welniak; D D Taub; R H Wiltrout; P A Taylor; D A Vallera; M Kopf; H Young; D L Longo; B R Blazar
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

8.  Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Authors:  H P Brok; P J Heidt; P H van der Meide; C Zurcher; J M Vossen
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

9.  Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.

Authors:  J C Unkeless
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

10.  A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells.

Authors:  M H Kaplan; A L Wurster; M J Grusby
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  70 in total

1.  Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Authors:  Keli L Hippen; Christoph Bucher; Dawn K Schirm; Amanda M Bearl; Ty Brender; Kathy A Mink; Kimberly S Waggie; Regis Peffault de Latour; Anne Janin; Julie M Curtsinger; Stacey R Dillon; Jeffrey S Miller; Gerard Socie; Bruce R Blazar
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

Review 2.  Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.

Authors:  James M Coghill; Stefanie Sarantopoulos; Timothy P Moran; William J Murphy; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2011-01-18       Impact factor: 22.113

3.  Expression of blood serum proteins and lymphocyte differentiation clusters after chronic occupational exposure to ionizing radiation.

Authors:  Valentina L Rybkina; Tamara V Azizova; Harry Scherthan; Viktor Meineke; Harald Doerr; Galina V Adamova; Olga V Teplyakova; Sergey V Osovets; Maria V Bannikova; Alexander V Zurochka
Journal:  Radiat Environ Biophys       Date:  2014-07-30       Impact factor: 1.925

4.  Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation.

Authors:  Mathias M Hauri-Hohl; Marcel P Keller; Jason Gill; Katrin Hafen; Esther Pachlatko; Thomas Boulay; Annick Peter; Georg A Holländer; Werner Krenger
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

5.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

6.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04

7.  Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.

Authors:  Tangsheng Yi; Ying Chen; Lin Wang; Gong Du; Daniel Huang; Dongchang Zhao; Heather Johnston; James Young; Ivan Todorov; Dale T Umetsu; Lieping Chen; Yoichiro Iwakura; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

8.  Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.

Authors:  Robert Zeiser; Sawsan Youssef; Jeanette Baker; Neeraja Kambham; Lawrence Steinman; Robert S Negrin
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

Review 9.  The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease.

Authors:  Anna Staffas; Marina Burgos da Silva; Marcel R M van den Brink
Journal:  Blood       Date:  2016-12-09       Impact factor: 22.113

10.  Allogeneic Th1 cells home to host bone marrow and spleen and mediate IFNγ-dependent aplasia.

Authors:  Joseph H Chewning; Weiwei Zhang; David A Randolph; C Scott Swindle; Trenton R Schoeb; Casey T Weaver
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.